An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome

Hepatology ◽  
2013 ◽  
Vol 58 (2) ◽  
pp. 752-761 ◽  
Author(s):  
Greg C. G. Hugenholtz ◽  
Jelle Adelmeijer ◽  
Joost C. M. Meijers ◽  
Robert J. Porte ◽  
R. Todd Stravitz ◽  
...  
2016 ◽  
Vol 35 (6) ◽  
pp. 432-440 ◽  
Author(s):  
K. S. Prasanna ◽  
Ashish Goel ◽  
G. Jayakumar Amirtharaj ◽  
Anup Ramachandran ◽  
K. A. Balasubramanian ◽  
...  

1999 ◽  
Vol 30 (3) ◽  
pp. 451-455 ◽  
Author(s):  
Liliana Albornoz ◽  
Daniel Alvarez ◽  
Juan Carlos Otaso ◽  
Adrián Gadano ◽  
Julieta Salviú ◽  
...  

2007 ◽  
Vol 24 (8) ◽  
pp. 1331-1338 ◽  
Author(s):  
Clarissa Oliveira De Oliveira ◽  
Alexandre Gard Reimer ◽  
Adriana Brondani Da Rocha ◽  
Ivana Grivicich ◽  
Rogério Fett Schneider ◽  
...  

Gut ◽  
2011 ◽  
Vol 60 (8) ◽  
pp. 1133-1138 ◽  
Author(s):  
V. La Mura ◽  
J. C. Reverter ◽  
A. Flores-Arroyo ◽  
S. Raffa ◽  
E. Reverter ◽  
...  

2020 ◽  

Raised levels of the blood coagulation protein von Willebrand factor (VWF) are now recognised to be important in patients with liver disease. The markedly raised plasma VWF levels in patients with acute liver failure and acute-on-chronic liver failure may contribute to the pathogenesis of liver failure, and of multi-organ failure, by impeding microcirculatory perfusion in the liver and the other affected vital organs. In this review, the authors present a brief introduction to VWF biology, discuss the ability of raised plasma VWF levels to accurately predict survival in different syndromes of liver diseases, speculate why plasma VWF levels are raised in liver failure syndromes, and examine the therapeutic potential of VWF-lowering therapies in these scenarios.


Sign in / Sign up

Export Citation Format

Share Document